MedTrace Logo

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

NCT02354170 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-07-26

No results posted yet for this study

Summary

The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.

Conditions

  • Central Serous Chorioretinopathy

Interventions

DRUG

Mifepristone

DRUG

Placebo

Sponsors & Collaborators

  • Ophthalmic Consultants of Boston

    collaborator OTHER

  • Roger Goldberg, M.D., MBA

    lead OTHER

Principal Investigators

  • Roger A Goldberg, M.D., MBA · Bay Area Retina Associates

  • Jeffrey S Heier, M.D. · Ophthalmic Consultants of Boston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-04-27
Completion
2017-04-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02354170 on ClinicalTrials.gov